INmune Bio Inc. filed a Regulation FD disclosure outlining its plans to seek regulatory approval for Ebstrocel, a treatment for RDEB, in the United Kingdom. The company submitted a pre-MAA package to UK regulators and targets a full Marketing Authorisation Application (MAA) submission for February 2027. INmune Bio anticipates potential UK approval in mid-2027, contingent on regulatory feedback.
The filing details the status of the company's two late-stage platforms targeting inflammation-driven disease. Ebstrocel, also referred to as CORDStrom, is the first of these platforms. The company has already submitted the pre-MAA package to UK authorities. Following this step, INmune Bio aims to file the complete MAA in February 2027. If approved, the company expects to receive authorization in the UK by mid-2027.
INmune Bio also outlined its U.S. strategy for Ebstrocel. The company plans to submit a Biologics License Application (BLA) in the second quarter of 2027. This timeline is subject to feedback from the U.S. Food and Drug Administration (FDA). The filing notes that Ebstrocel has not been approved by the FDA or any other regulatory body, and there is no assurance that approval will be granted.
To support access to the drug in select European and Middle East and North Africa (MENA) markets, INmune Bio entered into an agreement with Uniphar. This agreement supports planned named-patient access for the treatment.
The second platform discussed in the presentation is XPro1595, also known as pegipanermin. INmune Bio describes this candidate as a selective soluble TNF inhibitor. The company is currently conducting clinical trials for XPro1595, including the Phase 2 MINDFuL trial. Like Ebstrocel, XPro1595 has not received approval from the FDA or any other regulatory agency.
INmune Bio included extensive disclaimers regarding forward-looking statements in the disclosure. The company cautioned that actual results may differ materially from those anticipated due to various risks and uncertainties. These factors include the ability to raise capital to fund operations, protect intellectual property rights, and manage competition from other providers and products. The company also noted that clinical trials are in early stages, and there is no guarantee that specific outcomes will be achieved.
The presentation stated that pricing, reimbursement, market size, revenue potential, and cost-of-goods figures are illustrative. These figures are based on internal models and external sources believed to be reliable but are subject to significant uncertainties. These uncertainties include clinical outcomes, competitive dynamics, payer coverage, and macroeconomic factors. INmune Bio emphasized that it does not constitute an offer to sell or solicit an offer to buy any securities of the company.
The company noted that references to other products or companies are based on publicly available information as of the presentation date and may not be complete or current. Inclusion of these references does not imply endorsement or direct comparability. INmune Bio stated that it assumes no responsibility for the accuracy or completeness of information provided by third parties.
The filing serves as an investor presentation prepared by INmune Bio solely for information purposes. It does not constitute investment, legal, or medical advice. Readers are advised to conduct their own independent evaluation of the information provided.